CCM
ATXS

Camber Capital Management’s Astria Therapeutics ATXS Stock Holding History

Camber Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-16,667
Closed -$3.61M – 33
2016
Q4 		$3.61M Hold
16,667
– – 0.19% 34
2016
Q3 		$6.16M Hold
16,667
– – 0.27% 33
2016
Q2 		$3.7M Hold
16,667
– – 0.18% 44
2016
Q1 		$5.04M Hold
16,667
– – 0.3% 41
2015
Q4 		$7.93M Hold
16,667
– – 0.51% 35
2015
Q3 		$8.09M Buy
16,667
+1,207
+8% +$862K 0.69% 33
2015
Q2 		$11.3M Buy
+15,460
New +$11.7M 0.77% 33

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Camber Capital Management's ATXS Position: Q1 2017 in Review

Camber Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2017, closing a stake of 16,667 shares — an estimated $3.61M sold.

Camber Capital Management first reported a position in ATXS in Q2 2015 and held it in 7 quarters. The position peaked at $11.3M in Q2 2015. 23 funds tracked by Wall St. Rank hold ATXS as of Q1 2017.

  • Camber Capital Management reported no remaining Astria Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Camber Capital Management sold 16,667 Astria Therapeutics shares in Q1 2017, an estimated $3.61M.
  • Camber Capital Management first reported a position in Astria Therapeutics in Q2 2015 and held it in 7 quarters.
  • Camber Capital Management's Astria Therapeutics position peaked at $11.3M in Q2 2015.
  • 23 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2017.

Based on Camber Capital Management's 13F filing for Q1 2017, filed 15 May 2017.